SCHEMBL251333

SCHEMBL251333

C=CCOC(=O)CN(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.48
TDP1 Q9NUW8 1/20 0.44
CYP3A4 P08684 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
PKM P14618 1/20 0.37
MAPT P10636 1/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
ALDH1A1 P00352 8/20 0.35
GAA P10253 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
HSD17B10 Q99714 4/20 0.33
KDM4E B2RXH2 3/20 0.33
HPGD P15428 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
EPHX2 P34913 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycinebetaine SCHEMBL4263705 0.83 TSHR (0.37) TSHRTDP1NPSR1
SCHEMBL16264827 0.82 TSHR (0.47) TSHRTDP1CYP3A4NPSR1SMN1; SMN2
SCHEMBL170670 0.80 TSHR (0.46) TSHRTDP1CYP3A4NPSR1SMN1; SMN2
SCHEMBL628320 0.79 TSHR (0.55) TSHRTDP1CYP3A4NPSR1SMN1; SMN2
SCHEMBL9683567 0.79 TSHR (0.50) TSHRTDP1CYP3A4NPSR1SMN1; SMN2
SCHEMBL7919563 0.79 TSHR (0.46) TSHRTDP1CYP3A4NPSR1SMN1; SMN2
SCHEMBL11053476 0.79 TSHR (0.42) TSHRTDP1CYP3A4NPSR1SMN1; SMN2
SCHEMBL23254252 0.78 TDP1 (0.49) TSHRTDP1CYP3A4NPSR1SMN1; SMN2
SCHEMBL4594552 0.77 TSHR (0.41) TSHRTDP1CYP3A4NPSR1SMN1; SMN2
SCHEMBL11348362 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230055665-A1 DELIVERY CARRIER INTO CELL ITO, KABUSIKIKAISYA (JP) 2023-02-23 US claimed
US-20200246449-A1 INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME NANOBIO CORPORATION (US) 2020-08-06 US claimed
WO-2018204669-A1 INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME NANOBIO CORPORATION (US) 2018-11-08 WO claimed
EP-2729169-A1 HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE Nanobio Corporation (US) 2014-05-14 EP claimed
US-20130011443-A1 HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE NANOBIO CORPORATION 2013-01-10 US claimed
WO-2013006797-A1 HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE NANOBIO CORPORATION (US) 2013-01-10 WO claimed
US-20120276182-A1 METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS NANOBIO CORPORATION 2012-11-01 US claimed
US-20120219602-A1 METHODS FOR TREATING HERPES VIRUS INFECTIONS NANOBIO CORPORATION 2012-08-30 US claimed
US-8211879-B2 Cationic steroid antimicrobial compositions and methods of use BRIGHAM YOUNG UNIVERSITY (US) 2012-07-03 US claimed
US-20120064136-A1 ANTI-AGING AND WRINKLE TREATMENT METHODS USING NANOEMULSION COMPOSITIONS NANOBIO CORPORATION 2012-03-15 US claimed
EP-1203012-A2 REFOLDING OF MEMBRANE PROTEINS USING TWO DIFFERENT DETERGENTS M-Phasys GmbH (DE) 2002-05-08 EP claimed
WO-2001014407-A2 REFOLDING OF MEMBRANE PROTEINS, USING TWO DIFFERENT DETERGENTS M-PHASYS GMBH (DE) 2001-03-01 WO claimed
EP-1072312-A2 Acid resistant catalyst sheet and process for producing same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-01-31 EP claimed
EP-1072311-A2 Heat resistant catalyst sheet and process for producing same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-01-31 EP claimed
US-5900386-A GROUP IB OR 8 METALS ON SUPPORT DEGUSSA AKTIENGESELLSCHAFT (DE) 1999-05-04 US claimed
CN-1211193-A Contraceptive release systems with antibacterial and/or antiviral effect SCHERING AG (DE) 1999-03-17 CN claimed
EP-0576425-A1 METHOD FOR INACTIVATING ENVELOPED VIRUSES AND SPERM E.B. MICHAELS RESEARCH ASSOCIATES, INC. (US) 1994-01-05 EP claimed
WO-1992016201-A1 METHOD FOR INACTIVATING ENVELOPED VIRUSES AND SPERM E.B. MICHAELS RESEARCH ASSOCIATES, INC. (US) 1992-10-01 WO claimed
US-4252656-A AEROSOL CONTAINING CATIONIC POLYMER, SOFTENING AND FOAMING AGENTS, STABILIZER, HUMECTANT, WATER, AND PROPELLANT; LAUNDRY DRIERS COLGATE-PALMOLIVE COMPANY (US) 1981-02-24 US claimed
US-4041205-A SURFACTANTS AND A REINFORCEMENT SELECTED FROM CELLULOSE, PROTEIN, AND NYLON COLGATE-PALMOLIVE COMPANY (US) 1977-08-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230055665-A1 DELIVERY CARRIER INTO CELL CTSA, ATG4A, ATG7 TSHR 4448/4885TDP1 3619/4885CYP3A4 959/4885
US-20120219602-A1 METHODS FOR TREATING HERPES VIRUS INFECTIONS STING1, IFNG, NGF TSHR 4826/4885TDP1 1192/4885CYP3A4 4587/4885
US-20120276182-A1 METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS DPM1, ERG28, CYP51A1 TSHR 4862/4885TDP1 2530/4885CYP3A4 1201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.